A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis

Disease (cancer type)

Blood

Contact information

  • North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217

Patient Selection Criteria

1. Subject ≥ 18 years of age at the time of signing the informed consent form. 2. Subject with biopsy-proven breast cancer, lung cancer, NHL or prostate cancer starting myelosuppressive chemotherapy in the neoadjuvant/adjuvant or first line advanced/metastatic setting with at least 4 anticipated chemotherapy cycles. 3. Life expectancy > 6 months 4. Subject is starting or has recently (within the past 7 days) started myelosuppressive chemotherapy regimen with every 3 or 4-week cycle with a high FN risk > 20%, OR intermediate FN risk 10% to 20% risk (refer to Appendix E [only regimens listed within this appendix are allowed for enrollment]) and at least 1 risk factor for FN per Appendix F. Addition of non-cytotoxic targeted agents (eg, monoclonal antibodies, anti-angiogenic agents, and kinase inhibitors) to the listed chemotherapy regimens is permitted. 5. Subject who is starting adjuvant chemotherapy, neoadjuvant chemotherapy or first line chemotherapy in the metastatic setting and will be receiving at least 4 cycles of planned chemotherapy.

Research sponsor

Amgen

Reference ID#

20170758

State(s)

  • Florida

Linked Physicians

Back
To top